FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078752897> ?p ?o ?g. }

• W2078752897 endingPage "2344" @default.
• W2078752897 startingPage "2337" @default.
• W2078752897 abstract "Clinical trials of hyperfractionated radiation therapy and induction chemotherapy followed by standard radiation therapy have shown improved survival in patients with unresectable nonsmall cell lung cancer (NSCLC). Radiosensitization may improve local tumor control when chemotherapy is given concurrently with hyperfractionated radiation therapy, but also may increase toxicity. A Phase I/II trial, Radiation Therapy Oncology Group 90-15, was designed to evaluate whether this strategy could improve survival with acceptable toxicity and be part of a Phase III trial of chemoradiation sequencing.Vinblastine (5 mg/M2 weekly x 5 weeks) and cisplatin (75 mg/M2 days 1, 29, and 50) were given during twice-daily irradiation (1.2 Gy, 6 hours apart) to 69.6 Gy in 58 fractions in 6 weeks. Eligible patients had American Joint Committee on Cancer (AJCC) Stage II (unresected) or IIIA-B NSCLC and Karnofsky performance status 70 or greater; there were no weight loss restrictions.Of 42 eligible patients, 76% had greater than 5% weight loss, 45% had T4 primary tumors, and 62% were Stage IIIB. All protocol treatment was completed in 53%. Acute toxicity was predominantly hematologic with 19 of 42 (45%) having Grade 4 toxicity or higher, three (7%) with septic death. Ten of 42 (24%) had Grade 3 or higher esophagitis. There were two (4.7%) patients with Grade 3 or higher (1 lung and 1 esophagus) and two (4.7%) with Grade 4 or higher (1 lung and 1 hematologic) late toxicities. Median survival time was 12.2 months, with an overall 1-year survival of 54%, an estimated 2 year survival of 28% and a 1-year progression free survival of 38%.For patients with unresectable nonsmall cell lung cancer, who were not selected on the basis of weight loss, concurrent hyperfractionated irradiation and chemotherapy had more intense acute toxicity than hyperfractionation alone, but late toxicity was acceptable. One and 2-year survival rates were 54 and 28%, respectively." @default.
• W2078752897 created "2016-06-24" @default.
• W2078752897 creator A5010410691 @default.
• W2078752897 creator A5019357584 @default.
• W2078752897 creator A5026088869 @default.
• W2078752897 creator A5028842425 @default.
• W2078752897 creator A5030653008 @default.
• W2078752897 creator A5033516554 @default.
• W2078752897 creator A5068710491 @default.
• W2078752897 creator A5074247032 @default.
• W2078752897 creator A5085643126 @default.
• W2078752897 date "1995-05-01" @default.
• W2078752897 modified "2023-09-26" @default.
• W2078752897 title "Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of radiation therapy oncology group 90-15" @default.
• W2078752897 cites W1825780271 @default.
• W2078752897 cites W1975549289 @default.
• W2078752897 cites W1983339458 @default.
• W2078752897 cites W2000754251 @default.
• W2078752897 cites W2003111159 @default.
• W2078752897 cites W2007569149 @default.
• W2078752897 cites W2016871222 @default.
• W2078752897 cites W2017559081 @default.
• W2078752897 cites W2031555443 @default.
• W2078752897 cites W2040399379 @default.
• W2078752897 cites W2045313863 @default.
• W2078752897 cites W2062248834 @default.
• W2078752897 cites W2083859534 @default.
• W2078752897 cites W2091408714 @default.
• W2078752897 cites W2226077283 @default.
• W2078752897 cites W2317448174 @default.
• W2078752897 cites W4293241248 @default.
• W2078752897 doi "https://doi.org/10.1002/1097-0142(19950501)75:9<2337::aid-cncr2820750924>3.0.co;2-k" @default.
• W2078752897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7712445" @default.
• W2078752897 hasPublicationYear "1995" @default.
• W2078752897 type Work @default.
• W2078752897 sameAs 2078752897 @default.
• W2078752897 citedByCount "79" @default.
• W2078752897 countsByYear W20787528972012 @default.
• W2078752897 countsByYear W20787528972013 @default.
• W2078752897 countsByYear W20787528972014 @default.
• W2078752897 countsByYear W20787528972015 @default.
• W2078752897 countsByYear W20787528972016 @default.
• W2078752897 countsByYear W20787528972020 @default.
• W2078752897 countsByYear W20787528972021 @default.
• W2078752897 countsByYear W20787528972022 @default.
• W2078752897 crossrefType "journal-article" @default.
• W2078752897 hasAuthorship W2078752897A5010410691 @default.
• W2078752897 hasAuthorship W2078752897A5019357584 @default.
• W2078752897 hasAuthorship W2078752897A5026088869 @default.
• W2078752897 hasAuthorship W2078752897A5028842425 @default.
• W2078752897 hasAuthorship W2078752897A5030653008 @default.
• W2078752897 hasAuthorship W2078752897A5033516554 @default.
• W2078752897 hasAuthorship W2078752897A5068710491 @default.
• W2078752897 hasAuthorship W2078752897A5074247032 @default.
• W2078752897 hasAuthorship W2078752897A5085643126 @default.
• W2078752897 hasConcept C121608353 @default.
• W2078752897 hasConcept C126322002 @default.
• W2078752897 hasConcept C141071460 @default.
• W2078752897 hasConcept C143998085 @default.
• W2078752897 hasConcept C2776256026 @default.
• W2078752897 hasConcept C2776694085 @default.
• W2078752897 hasConcept C2776907518 @default.
• W2078752897 hasConcept C2777819096 @default.
• W2078752897 hasConcept C2779134260 @default.
• W2078752897 hasConcept C2779920096 @default.
• W2078752897 hasConcept C29730261 @default.
• W2078752897 hasConcept C43270747 @default.
• W2078752897 hasConcept C509974204 @default.
• W2078752897 hasConcept C71924100 @default.
• W2078752897 hasConcept C90924648 @default.
• W2078752897 hasConceptScore W2078752897C121608353 @default.
• W2078752897 hasConceptScore W2078752897C126322002 @default.
• W2078752897 hasConceptScore W2078752897C141071460 @default.
• W2078752897 hasConceptScore W2078752897C143998085 @default.
• W2078752897 hasConceptScore W2078752897C2776256026 @default.
• W2078752897 hasConceptScore W2078752897C2776694085 @default.
• W2078752897 hasConceptScore W2078752897C2776907518 @default.
• W2078752897 hasConceptScore W2078752897C2777819096 @default.
• W2078752897 hasConceptScore W2078752897C2779134260 @default.
• W2078752897 hasConceptScore W2078752897C2779920096 @default.
• W2078752897 hasConceptScore W2078752897C29730261 @default.
• W2078752897 hasConceptScore W2078752897C43270747 @default.
• W2078752897 hasConceptScore W2078752897C509974204 @default.
• W2078752897 hasConceptScore W2078752897C71924100 @default.
• W2078752897 hasConceptScore W2078752897C90924648 @default.
• W2078752897 hasIssue "9" @default.
• W2078752897 hasLocation W20787528971 @default.
• W2078752897 hasLocation W20787528972 @default.
• W2078752897 hasOpenAccess W2078752897 @default.
• W2078752897 hasPrimaryLocation W20787528971 @default.
• W2078752897 hasRelatedWork W1967957440 @default.
• W2078752897 hasRelatedWork W2010771602 @default.
• W2078752897 hasRelatedWork W2053036048 @default.
• W2078752897 hasRelatedWork W2056156526 @default.
• W2078752897 hasRelatedWork W2092524766 @default.
• W2078752897 hasRelatedWork W2234839489 @default.
• W2078752897 hasRelatedWork W2357406576 @default.
• W2078752897 hasRelatedWork W2411319260 @default.

• next